Search / Trial NCT00001087

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of December 10, 2023

Completed

Keywords

Drug Therapy, Combination Antiviral Agents Hiv Protease Inhibitors Ritonavir Saquinavir Nelfinavir Reverse Transcriptase Inhibitors Adenine Anti Hiv Agents Efavirenz

Description

Achieving viral suppression has been widely endorsed as the primary goal of HIV therapy, yet there are few established guidelines to provide the framework by which to devise combinations of different classes of drugs which will not only enhance the potential for achieving viral suppression while reducing the risk of toxicity but will also preserve therapeutic options for future use. This study includes 2 antiretroviral compounds, NFV (a protease inhibitor [PI]) and EFV (a nonnucleoside reverse transcriptase inhibitor [NNRTI]), for use either alone or in combination with reverse transcriptas...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Required:
  • Chemoprophylaxis for Pneumocystis carinii pneumonia for all patients who have a CD4 count of 200 cells/mm3 or less.
  • Allowed:
  • Topical and oral antifungal except for oral ketoconazole.
  • Treatment, maintenance, or chemoprophylaxis with approved agents for opportunistic infections as clinically indicated.
  • All antibiotics as clinically indicated.
  • Systemic corticosteroid use for no more than 21 days for acute problems as medically indicated. Note: Steroid use for more than 21 days is considered on a case-by-case basis.
  • Recombinant erythropoietin (rEPO) and granulocyte colony-stimulating factor (G-CSF) as medically indicated.
  • Regularly prescribed medications such as antipyretics, analgesics, allergy medications, antidepressants, sleep medications, oral contraceptives, megestrol acetate, testosterone, or any other medications as medically indicated.
  • [AS PER AMENDMENT 4/25/00:
  • Allowed with caution:
  • Pentamidine, allopurinol, hydroxyurea. Use of these medications may increase exposure to ddI.]
  • Concurrent Treatment:
  • Allowed:
  • Dependency of less than 3 units of blood per 21-day period.
  • Alternative therapies such as acupuncture and visualization techniques.
  • Patients must have:
  • HIV infection documented by a licensed ELISA and confirmed by Western blot, positive HIV culture, positive HIV antigen, positive plasma HIV RNA, or second antibody test positive by a method other than ELISA. Repeat HIV-antibody testing is not required for enrollment in this trial (implicit in patients having been enrolled in ACTG 302/303).
  • Signed, informed consent from parent or legal guardian for patients under 18 years of age.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following conditions or symptoms are excluded:
  • Inability to tolerate ddI at 200-400 mg/day, 3TC at 300 mg/day, or d4T at 60-80 mg/day, with intolerance defined as recurrent toxicities requiring dose interruptions and reductions or permanent discontinuation of the drugs (other than Grade 3 or 4 anemia).
  • Grade 2 or higher peripheral neuropathy.
  • Malignancy requiring systemic therapy.
  • Co-enrollment in other antiretroviral protocols; co-enrollment in other ACTG protocols is encouraged, particularly those involving prophylaxis for opportunistic infections.
  • Concurrent Medication:
  • Excluded:
  • All antiretroviral therapies other than study medications.
  • Investigational drugs and vaccines without specific approval from the Protocol Chair/Vice Chairs.
  • Systemic cytotoxic chemotherapy.
  • Interferon, interleukins, GM-CSF, and HIV-1 vaccines.
  • Rifabutin and rifampin.
  • Ketoconazole, astemizole, cisapride, midazolam, terfenadine, and triazolam.
  • Acute therapy for an infection or other medical illness.
  • Herbal medications.
  • Vitamins. [10. AS PER AMENDMENT 3/5/98:
  • Ergot alkaloids or drugs containing derivatives or ergot alkaloids.]
  • Patients with the following prior conditions are excluded:
  • History of acute or chronic pancreatitis.
  • Prior Medication:
  • Excluded:
  • PIs.
  • NNRTIs.
  • Acute therapy for an infection or other medical illness within 14 days prior to the time of study entry.
  • Chronic long-term steroid use is not permitted unless it is within physiologic replacement levels; protocol chair/vice chairs must be contacted in these instances.
  • Risk Behavior:
  • Excluded:
  • Current ethanol abuse by personal history or a report from a primary physician.

Attachments

readout_NCT00001087_2023-12-10.pdf

4.5 MB

NCT00001087_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Chicago, Illinois, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Baltimore, Maryland, United States

New York, New York, United States

San Juan, , Puerto Rico

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0